Literature DB >> 24277475

Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.

Karin Lindvall1, Sylvia von Mackensen, Sölve Elmståhl, Kate Khair, Ann Marie Stain, Rolf Ljung, Erik Berntorp.   

Abstract

INTRODUCTION: Having a child with a chronic disease often increases the burden in the family with more hospital visits, treatment administration, and increased worries for the ill child. A cross-sectional, international, multi-centre study in caregivers of children <18 years with haemophilia and inhibitor was performed at Haemophilia Treatment Centres in Sweden, UK, and Canada to evaluate caregivers' burden and their health-related quality of life (HRQoL) compared to that of caregivers of children on prophylaxis without inhibitors and caregivers of healthy children.
METHODS: Caregivers of children with haemophilia completed several questionnaires (SF-36, Visual Analogue Scale of Interference (VAS), Caregivers' Burden Scale and Impact on Family Scale (IOF). Caregivers of healthy children completed only the SF-36. In addition, socio-demographic data were collected.
RESULTS: In total, 143 caregivers were included in the study. Comparing the two haemophilia groups with caregivers of healthy children revealed significant differences for all SF-34 domains except 'pain' and 'general health'. In Caregivers' Burden Scale, caregivers of children with inhibitors reported higher impact of haemophilia (P < 0.0001) and higher impact on VAS (P < 0.0001) compared to caregivers of children without inhibitors. In IOF, caregivers of children with inhibitors reported significant negative impact of the disease, except for aspect of coping.
CONCLUSION: Caregivers of children with inhibitors reported higher impact of the disease compared to caregivers of children with no inhibitors. No differences between mothers and fathers in the two groups for SF-36, Caregivers' Burden Scale, VAS and IOF, except for domain pain in SF-36 where mothers reported higher impairments.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  caregiver; caregivers' burden scale; haemophilia; health-related quality of life; impact on family scale (IOF); inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24277475     DOI: 10.1002/pbc.24856

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  15 in total

Review 1.  Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches.

Authors:  Shannon L Meeks; Glaivy Batsuli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

2.  A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy.

Authors:  Marieke C Punt; Lorynn Teela; Kathelijn Fischer; Kitty W M Bloemenkamp; A Titia Lely; Mariette H E Driessens; Lynnda Pekel; Lotte Haverman; Karin P M van Galen
Journal:  Haemophilia       Date:  2021-08-20       Impact factor: 4.263

Review 3.  Gene therapy for immune tolerance induction in hemophilia with inhibitors.

Authors:  V R Arruda; B J Samelson-Jones
Journal:  J Thromb Haemost       Date:  2016-05-14       Impact factor: 5.824

Review 4.  Burden and quality of life of mothers of children and adolescents with chronic illnesses: an integrative review.

Authors:  Eliza Cristina Macedo; Leila Rangel da Silva; Mirian Santos Paiva; Maria Natália Pereira Ramos
Journal:  Rev Lat Am Enfermagem       Date:  2015 Jul-Aug

5.  Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project.

Authors:  Chiara Biasoli; Erminia Baldacci; Antonio Coppola; Raimondo De Cristofaro; Matteo N D Di Minno; Giuseppe Lassandro; Silvia Linari; Maria E Mancuso; Mariasanta Napolitano; Gianluigi Pasta; Angiola Rocino
Journal:  Blood Transfus       Date:  2021-10-15       Impact factor: 3.443

6.  Family caregivers of children and adolescents with rare diseases: a novel palliative care intervention.

Authors:  Maureen E Lyon; Jessica D Thompkins; Karen Fratantoni; Jamie L Fraser; Sandra E Schellinger; Linda Briggs; Sarah Friebert; Samar Aoun; Yao Iris Cheng; Jichuan Wang
Journal:  BMJ Support Palliat Care       Date:  2019-07-25       Impact factor: 4.633

Review 7.  European principles of inhibitor management in patients with haemophilia.

Authors:  P L F Giangrande; C Hermans; B O'Mahony; P de Kleijn; M Bedford; A Batorova; J Blatný; K Jansone
Journal:  Orphanet J Rare Dis       Date:  2018-04-27       Impact factor: 4.123

Review 8.  Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

Review 9.  Being the Pillar for Children with Rare Diseases-A Systematic Review on Parental Quality of Life.

Authors:  Johannes Boettcher; Michael Boettcher; Silke Wiegand-Grefe; Holger Zapf
Journal:  Int J Environ Res Public Health       Date:  2021-05-08       Impact factor: 3.390

Review 10.  Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.

Authors:  Johnny N Mahlangu
Journal:  Ther Adv Hematol       Date:  2018-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.